You are here: Industry Insights > atopic dermatitis

News List

Dupixent approved in EU for atopic dermatitis in children pharmatimes
December 01, 2020
The European Commission has approved Sanofi and Regeneron’s biologic treatment Dupixent for the treatment of children aged six to 11 years with severe atopic dermatitis.
Arena Pharmaceuticals Reports Topline Results from Atopic Dermatitis Trial americanpharmaceuticalreview
November 20, 2020
Arena Pharmaceuticals announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of moderate-to-severe atopic dermatitis.
Pfizer’s abrocitinib scores another phase III win in atopic dermatitis pharmatimes
November 12, 2020
Pfizer’s investigational oral Janus kinase 1 (JAK1) inhibitor abrocitinib has scored positive top-line results in a phase III atopic dermatitis trial.
FDA grants priority review and EMA accepts regulatory submission for Pfizer’s abrocitinib pharmaceutical-business-review
October 30, 2020
Pfizer announced that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Priority Review designation to the company’s New Drug Application (NDA) for abrocitinib (100mg and 200mg) ...
Micreos initiates clinical trial to evaluate endolysin-drug in atopic dermatitis pharmaceutical-business-review
September 27, 2020
Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to ...
Hoth Therapeutic Submits Ethics Approval Request for Atopic Dermatitis Trial americanpharmaceuticalreview
August 18, 2020
Hoth Therapeutics has submitted for ethics approval in Australia for its planned Clinical study of its therapeutic BioLexa for Atopic Dermatitis. The ethics submission was made to the Bellberry Human Research Ethics Committee in Australia.
Study Shows RINVOQ, Topical Corticosteroids Improves Atopic Dermatitis Symptoms americanpharmaceuticalreview
August 04, 2020
AbbVie announced upadacitinib (15 mg and 30 mg, once daily) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in AD Up, the third pivotal Phase 3 study of RINVOQ in atopic dermatitis.
AbbVie's Rinvoq hits targets in atopic dermatitis trial pharmatimes
July 23, 2020
AbbVie's Rinvoq (upadacitinib) monotherapy has hit both primary and secondary targets in the Measure Up 2 trial, the second Phase III study in individuals with moderate to severe atopic dermatitis.
Sanofi-Regeneron Dupixent secures China approval for atopic dermatitis pharmaceutical-technology
June 23, 2020
Sanofi and Regeneron Pharmaceuticals’ Dupixent (dupilumab) has received approval from China’s National Medical Products Administration (NMPA) to treat adults with moderate to severe atopic dermatitis.
AbbVie's Rinvoq shows potential for atopic dermatitis pharmatimes
June 22, 2020
AbbVie has presented new data showing that Rinvoq (upadacitinib) monotherapy induced significant improvements in skin clearance in people with atopic dermatitis.

Previous page 1 2 3 4 Next page